Printer Friendly

CAMBRIDGE BIOTECH CORPORATION AND PASTEUR MERIEUX IN INFLUENZA VACCINE PARTNERSHIP

 CAMBRIDGE BIOTECH CORPORATION AND PASTEUR MERIEUX
 IN INFLUENZA VACCINE PARTNERSHIP
 WORCESTER, Mass., Aug. 4 /PRNewswire/ -- Cambridge Biotech Corporation (NASDAQ: CBCX) today announced that it has reached agreement in principle with Pasteur Merieux Serums & Vaccins, an international French health care company, to allow Pasteur Merieux to use Cambridge's Stimulon(tm) adjuvant in a new vaccine against influenza. The influenza vaccines presently marketed address an estimated world market in the order of $200 million per year.
 The agreement involves an initial license fee from Merieux to Cambridge, plus additional fees as the vaccine moves through clinical trials. Once the vaccine is commercialized, Cambridge will supply the adjuvant for formulation, and Cambridge will also receive a royalty on sales.
 "We are pleased to have Pasteur Merieux, the market leader in flu vaccines, as one of our adjuvant partners in the human vaccine development area," said Patrick J. Leonard, president and CEO of Cambridge. "The new partnership further demonstrates the value of our adjuvant in a wide range of vaccines." Exact financial terms were not disclosed.
 Cambridge Biotech is active in the development of vaccines, adjuvants and monoclonal antibodies as the basis for vaccines, therapeutics and diagnostic products for humans and animals. The company is a significant developer, manufacturer and distributor of viral diagnostic screening and confirmatory products utilizing recombinant technology.
 -0- 8/4/92
 /CONTACT: Peter P. Hartman, vice president, finance and CFO of Cambridge Biotech, 508-797-5777/
 (CBCX) CO: Cambridge Biotech Corporation ST: Massachusetts IN: MTC SU:


CN -- NE002 -- 6486 08/04/92 08:32 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 4, 1992
Words:253
Previous Article:SILICON GRAPHICS FORMS NEW OEM OPERATIONS ORGANIZATION; COMPANY STRENGTHENS PROGRAMS FOR OEM PARTNERS
Next Article:ALLSTATE INSURANCE COMPANY AND IVHS FOUNDER ACCUSED OF PATENT INFRINGEMENT BY VEHICLE RADAR SAFETY SYSTEMS
Topics:


Related Articles
CAMBRIDGE BIOTECH GRANTS SUBLICENSE TO GENENTECH FOR DEVELOPMENT OF AIDS VACCINE
CAMBRIDGE BIOTECH LICENSES ITS STIMULON ADJUVANT TO AMERICAN CYANAMID
RGENE ESTABLISHES COLLABORATION WITH PASTEUR MERIEUX-CONNAUGHT TO DEVELOP NOVEL APPLICATIONS OF DC-CHOLESTEROL CATIONIC LIPID
ORAVAX, INC. TO BE AWARDED U.S. PATENT ON VACCINE AGAINST HELICOBACTER PYLORI INFECTION
Corixa Corporation Establishes Vaccine Adjuvant Collaboration With Pasteur Merieux Connaught
Clinical Trial Demonstrates Pasteur Merieux Connaught's Candidate Lyme Disease Vaccine Reduces Overall Occurrence of Lyme Disease in Participants
Clinical Trial Demonstrates Pasteur Merieux Connaught's Candidate Lyme Disease Vaccine Reduces Overall Occurrence of Lyme Disease in Participants
North American Vaccine Receives $6 Million Milestone Payment Under Agreements With Pasteur Merieux-Connaught To Develop New Conjugate Vaccine For...
Corixa Announces Extension of Vaccine Adjuvant Research Agreement and Option Agreement With Pasteur Merieux Connaught
BTG Licenses Novel Vaccine Technology to Pasteur Merieux Connaught

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters